Top 10 Companies in the 1,1‑Cyclopropanediacetonitrile (CAS 20778‑47‑6) Market (2026): Market Leaders Driving Global Specialty Chemistry

MARKET INSIGHTS

The Global 1,1‑Cyclopropanediacetonitrile (CAS 20778‑47‑6) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2 % during the forecast period.

1,1‑Cyclopropanediacetonitrile is a specialized organic compound featuring a cyclopropane ring substituted with two acetonitrile groups at the 1,1‑position. It serves as a versatile chemical intermediate, primarily utilized in the synthesis of pharmaceuticals, agrochemicals, and fine chemical formulations. Its unique bicyclic and nitrile‑bearing structure makes it particularly valuable in the development of complex molecular scaffolds used in medicinal chemistry research and active pharmaceutical ingredient (API) manufacturing.

The market is witnessing steady growth driven by rising demand for advanced pharmaceutical intermediates and the expanding scope of agrochemical research globally. The increasing focus on drug discovery programs and the growing need for structurally diverse building blocks in synthetic chemistry are key factors propelling adoption. Furthermore, advancements in cyclopropane‑based chemistry and the broadening application of dinitrile compounds in specialty chemical synthesis continue to open new avenues for market participants operating across North America, Europe, and Asia‑Pacific.

1,1‑Cyclopropanediacetonitrile (CAS 20778‑47‑6) Market – View in Detailed Research Report

Top 10 Companies in the 1,1‑Cyclopropanediacetonitrile Market

1. Hairui Fine Chemicals Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: Pharmaceutical‑grade 1,1‑Cyclopropanediacetonitrile with >99% purity
Hairui has invested heavily in scale‑up reactors and inline purification to deliver consistent, GMP‑compliant intermediates. The company’s sustainability initiative focuses on zero‑waste nitrile synthesis, achieving a 15 % reduction in hazardous by‑products over the last three years.
Highlights:

• Dedicated production line for >100 kg/day throughput
• ISO 9001 and ISO 14001 certified facilities
• Partnerships with Chinese pharma R&D hubs

2. Capot Chemical Co., Ltd. (China)

Headquarters: Shenzhen, China
Key Offering: High‑purity dinitrile intermediates for agrochemical and fine‑chemical synthesis
Capot’s green chemistry program leverages solvent‑free cyclopropanation, cutting CO₂ emissions by 20 % compared to conventional routes. The firm’s R&D pipeline includes next‑generation herbicide scaffolds that rely on 1,1‑Cyclopropanediacetonitrile as a core building block.
Highlights:

• Capacity of 80 kg/day with 98–99% purity
• Active collaboration with EU agrochemical research consortia
• Rapid custom synthesis service for CROs

3. Hebei Guanlang Biotechnology Co., Ltd. (China)

Headquarters: Handan, China
Key Offering: Research‑grade dinitrile intermediates for academic and industrial synthesis
Hebei Guanlang focuses on delivering ultra‑pure intermediates (<99.5% purity) for academic laboratories, supporting cutting‑edge medicinal chemistry projects. Their sustainability strategy includes waste‑valorisation of nitrile by‑products into nitrogen‑rich polymers.
Highlights:

• Annual production of 30 kg of research‑grade material
• Partnerships with top Chinese universities
• Custom synthesis catalog with rapid turnaround

4. Matrix Scientific (USA)

Headquarters: Columbia, Maryland, USA
Key Offering: High‑purity 1,1‑Cyclopropanediacetonitrile for pharmaceutical and agrochemical R&D
Matrix Scientific’s green chemistry platform uses recyclable solvents and biocatalytic steps to reduce environmental impact. The company supplies a robust library of dinitrile building blocks for US biotech firms, emphasizing fast, compliant delivery.
Highlights:

• Capacity of 40 kg/year with >99% purity
• ISO 9001 certification and GHS‑compliant safety data sheets
• Strong presence in the US pharma supply chain

5. Wuhan Fortuna Chemical Co., Ltd. (China)

Headquarters: Wuhan, China
Key Offering: Industrial‑grade 1,1‑Cyclopropanediacetonitrile for large‑scale synthesis
Fortuna’s focus on process optimisation has enabled a 30 % increase in yield for cyclopropanation reactions, reducing raw material consumption. The firm’s sustainability commitment includes energy‑efficient reactors and a closed‑loop water system.
Highlights:

• Production capacity of 120 kg/month
• Compliance with REACH and RoHS standards
• Dedicated customer support for large‑scale projects

6. Shanghai Aladdin Biochemical Technology Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: Research‑grade intermediates for fine‑chemical synthesis
Aladdin Biochemical’s modular synthesis platform allows rapid scale‑up of 1,1‑Cyclopropanediacetonitrile for specialty chemical applications. Their sustainability focus includes zero‑liquid‑discharge operations.
Highlights:

• Annual throughput of 25 kg of research‑grade material
• Active collaboration with Chinese fine‑chemical OEMs
• Custom synthesis and purification services

7. Enamine Ltd. (Ukraine)

Headquarters: Kharkiv, Ukraine
Key Offering: High‑purity dinitrile intermediates for medicinal chemistry and agrochemical research
Enamine’s green chemistry initiatives focus on solvent‑free synthesis and the use of renewable feedstocks, reducing the carbon footprint of 1,1‑Cyclopropanediacetonitrile production. The company supplies a broad catalog to European and US researchers.
Highlights:

• Capacity of 60 kg/year with >98% purity
• ISO 9001 and ISO 14001 certifications
• Rapid delivery to EU CROs and pharma labs

8. Anhui Wokai Biotechnology Co., Ltd. (China)

Headquarters: Hefei, China
Key Offering: Pharmaceutical‑grade intermediates for API development
Wokai Biotechnology emphasizes process robustness and regulatory compliance, offering 99.5% purity material for pharma clients. Their sustainability program includes renewable energy sourcing and waste‑to‑energy conversion for by‑products.
Highlights:

• Production capacity of 70 kg/year
• Strong ties with Chinese generic drug manufacturers
• Custom synthesis support for early‑stage discovery

9. Shandong Baimao Huiyuan Bio‑Technology Co., Ltd. (China)

Headquarters: Qingdao, China
Key Offering: Research‑grade dinitrile intermediates for academic and industrial use
Baimao Huiyuan focuses on delivering ultra‑pure intermediates for academic research, with a strong emphasis on analytical support and rapid turnaround. Their sustainability efforts include a closed‑loop solvent recovery system.
Highlights:

• Annual output of 20 kg of research‑grade material
• Collaboration with Chinese universities and research institutes
• High‑quality safety data sheets compliant with GHS

10. Hebei Mojin Biotechnology Co., Ltd. (China)

Headquarters: Handan, China
Key Offering: Pharmaceutical‑grade 1,1‑Cyclopropanediacetonitrile for API synthesis
Hebei Mojin’s focus on process optimisation and quality control has led to a 25 % improvement in yield for cyclopropanation steps. The firm’s sustainability strategy includes waste‑minimisation and energy‑efficient production.
Highlights:

• Capacity of 90 kg/year with >99% purity
• ISO 9001 and ISO 14001 certifications
• Strong relationships with Chinese pharma OEMs

Download FREE Sample Report: 1,1‑Cyclopropanediacetonitrile (CAS 20778‑47‑6) Market

Get Full Report Here: 1,1‑Cyclopropanediacetonitrile (CAS 20778‑47‑6) Market – View in Detailed Research Report

Outlook

The 2026‑2034 forecast period will see the 1,1‑Cyclopropanediacetonitrile market solidify its position as a critical intermediate for both pharmaceutical and agrochemical sectors. The continued emphasis on early‑stage drug discovery, coupled with expanding agrochemical pipelines, will sustain demand for high‑purity intermediates. The market will also benefit from the growing role of CDMOs, which will increase the availability of this building block through expanded reagent catalogs and streamline supply chains for end users.

Future Trends

Emerging developments in cyclopropane‑based chemistry, particularly in fragment‑based drug discovery, will drive the adoption of 1,1‑Cyclopropanediacetonitrile as a key scaffold for novel therapeutics. Advances in green chemistry and process automation are expected to reduce production costs and environmental impact, further enhancing the compound’s appeal. Additionally, the rise of functional polymer research and nitrogen‑rich energetic materials offers new application avenues, potentially expanding the market beyond traditional pharmaceutical and agrochemical uses.